Dual Therapy With Boosted Darunavir + Dolutegravir
Status:
Completed
Trial end date:
2018-05-31
Target enrollment:
Participant gender:
Summary
A switch strategy to investigate whether a dual therapy with Ritonavir-boosted (RTV)
Darunavir (DRV) + Dolutegravir (DTG) over 48 weeks is non-inferior to a continuous standard
of care therapy with RTV-boosted DRV in combination with 2 Nucleosidic Reverse Transcriptase
Inhibitors (NRTIs) in HIV patients, who are on a stable antiretroviral therapy (ART) with
RTV-boosted DRV in combination with 2 NRTIs.